Brandon Couillard
Stock Analyst at Wells Fargo
(4.92)
# 214
Out of 5,014 analysts
714
Total ratings
63.9%
Success rate
19.2%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIO Bio-Rad Laboratories | Rated: Hold | n/a | $377.71 | - | 58 | Sep 29, 2026 | |
| BLLN BillionToOne | Rated: Hold | n/a | $106.44 | - | 7 | Sep 29, 2026 | |
| BRKR Bruker | Rated: Hold | n/a | $64.75 | - | 41 | Sep 29, 2026 | |
| CDNA CareDx | Rated: Hold | n/a | $65.00 | - | 12 | Sep 29, 2026 | |
| DHR Danaher | Rated: Hold | n/a | $221.55 | - | 54 | Sep 29, 2026 | |
| GH Guardant Health | Rated: Hold | n/a | $178.36 | - | 10 | Sep 29, 2026 | |
| MLAB Mesa Laboratories | Rated: Hold | n/a | $129.94 | - | 16 | Sep 29, 2026 | |
| MRVI Maravai LifeSciences Holdings | Rated: Hold | n/a | $7.66 | - | 13 | Sep 29, 2026 | |
| MTD Mettler-Toledo International | Rated: Hold | n/a | $1,510.95 | - | 26 | Sep 29, 2026 | |
| MYGN Myriad Genetics | Rated: Hold | n/a | $4.31 | - | 32 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $413.31 | - | 7 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $152.89 | - | 39 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $72.30 | - | 16 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $615 | $675.05 | -8.90% | 42 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $72.47 | -14.45% | 6 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $165 → $160 | $172.31 | -7.14% | 55 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $355 → $370 | $439.39 | -15.79% | 29 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $190 → $180 | $192.23 | -6.36% | 29 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $14 | $15.05 | -6.98% | 18 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $17 | $17.40 | n/a | 4 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $88 → $81 | $83.97 | n/a | 21 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $38 | $8.86 | n/a | 25 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $23 | $23.47 | n/a | 6 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $305 → $325 | $145.35 | n/a | 43 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $364.04 | n/a | 26 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $11 | $1.42 | n/a | 2 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $26 | $1.39 | n/a | 7 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $16 → $15 | $3.92 | n/a | 20 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $280 → $300 | $179.00 | n/a | 17 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3.5 → $4.5 | $1.61 | n/a | 16 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 → $1.75 | $0.212 | n/a | 11 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $116 | $60.00 | n/a | 1 | May 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $26 | $43.76 | n/a | 5 | Nov 22, 2016 |
Bio-Rad Laboratories
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $377.71
Upside: -
BillionToOne
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $106.44
Upside: -
Bruker
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $64.75
Upside: -
CareDx
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $65.00
Upside: -
Danaher
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $221.55
Upside: -
Guardant Health
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $178.36
Upside: -
Mesa Laboratories
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $129.94
Upside: -
Maravai LifeSciences Holdings
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $7.66
Upside: -
Mettler-Toledo International
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $1,510.95
Upside: -
Myriad Genetics
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $4.31
Upside: -
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $413.31
Upside: -
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $152.89
Upside: -
Sep 29, 2026
Rated: Hold
Price Target: n/a
Current: $72.30
Upside: -
Jul 23, 2026
Rated: Buy
Price Target: $615
Current: $675.05
Upside: -8.90%
Jun 26, 2026
Reiterated: Buy
Price Target: $62
Current: $72.47
Upside: -14.45%
May 28, 2026
Reiterated: Buy
Price Target: $165 → $160
Current: $172.31
Upside: -7.14%
May 14, 2026
Reiterated: Hold
Price Target: $355 → $370
Current: $439.39
Upside: -15.79%
Feb 25, 2026
Reiterated: Buy
Price Target: $190 → $180
Current: $192.23
Upside: -6.36%
Feb 13, 2026
Reiterated: Buy
Price Target: $16 → $14
Current: $15.05
Upside: -6.98%
Mar 13, 2024
Reiterated: Buy
Price Target: $21 → $17
Current: $17.40
Upside: n/a
Mar 6, 2024
Reiterated: Hold
Price Target: $88 → $81
Current: $83.97
Upside: n/a
Feb 29, 2024
Reiterated: Buy
Price Target: $36 → $38
Current: $8.86
Upside: n/a
Feb 9, 2024
Downgraded: Hold
Price Target: $32 → $23
Current: $23.47
Upside: n/a
Feb 1, 2024
Reiterated: Buy
Price Target: $305 → $325
Current: $145.35
Upside: n/a
Aug 29, 2022
Reiterated: Buy
Price Target: $200
Current: $364.04
Upside: n/a
May 4, 2022
Reiterated: Buy
Price Target: $13 → $11
Current: $1.42
Upside: n/a
Jun 18, 2021
Rated: Buy
Price Target: $26
Current: $1.39
Upside: n/a
Aug 6, 2020
Rated: Hold
Price Target: $16 → $15
Current: $3.92
Upside: n/a
May 18, 2020
Reiterated: Buy
Price Target: $280 → $300
Current: $179.00
Upside: n/a
Aug 8, 2018
Reiterated: Hold
Price Target: $3.5 → $4.5
Current: $1.61
Upside: n/a
Jul 27, 2018
Reiterated: Buy
Price Target: $2 → $1.75
Current: $0.212
Upside: n/a
May 31, 2017
Reiterated: Buy
Price Target: $116
Current: $60.00
Upside: n/a
Nov 22, 2016
Reiterated: Hold
Price Target: $26
Current: $43.76
Upside: n/a